23andMe shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.
Portfolio Pulse from Benzinga Newsdesk
23andMe's stock price is trading lower following the announcement of disappointing Q3 financial results and a revenue guidance for FY24 that falls below market expectations.
February 08, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
23andMe's shares are down after the company announced worse-than-expected Q3 financial results and provided FY24 revenue guidance that did not meet analysts' expectations.
The negative impact on 23andMe's stock price is directly related to the company's announcement of disappointing Q3 financial results and lower than expected revenue guidance for FY24. This kind of financial performance and outlook often leads to a loss of investor confidence and a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100